Response

Zhou and colleagues provide important real-world evidence on clozapine-associated neutropenia using a 20-year population-based cohort from Hong Kong. ^{Reference Zhou, Luo, Siskind, Northwood, Tang and Lui1} Among 43 145 patients with schizophrenia spectrum disorders, including 4868 incident clozapine users, clozapine was associated with higher rates of serious and minor neutropenia than non-clozapine second-generation antipsychotics (SGAs). However, the excess risk was concentrated during the early treatment period. The incidence was particularly elevated during the first 18 weeks, subsequently declined and became comparable with that associated with other SGAs by approximately 1 year. ^{Reference Zhou, Luo, Siskind, Northwood, Tang and Lui1} These findings provide further support for reconsidering uniform, prolonged haematological monitoring and for developing more risk-stratified approaches.

The major contribution of the Hong Kong study is therefore not simply its estimate of incidence, but its demonstration that haematological risk is dynamic. The reported rates of serious neutropenia and agranulocytosis were higher among clozapine users than among SGA users, but the temporal distribution suggests that the excess risk is predominantly front-loaded. ^{Reference Zhou, Luo, Siskind, Northwood, Tang and Lui1} This observation is consistent with recent international evidence and consensus recommendations supporting intensive monitoring during the early months of treatment, followed by less frequent monitoring thereafter. ^{Reference Siskind, Northwood, Pillinger, Chan, Correll and Cotes2–Reference Verdoux, Bittner, Hasan, Qubad, Wagner and Lepetit4} Nevertheless, the findings should not be interpreted as indicating that all patients can safely undergo identical reductions in monitoring.

One particularly important issue emerges when the Hong Kong findings are compared with recent Japanese nationwide data. Kikuchi and colleagues analysed 18 189 patients registered in Japan’s Clozaril Patient Monitoring Service and identified 138 cases of clozapine-induced agranulocytosis (CIA; 0.76%). ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} No CIA occurred during the first 30 days, whereas the median time to onset was 78 days and 63.0% of cases occurred within 90 days. ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} Thus, at first sight, the absence of CIA during the first month in Japan appears somewhat different from the prominent early risk reported by Zhou and colleagues.

This apparent discrepancy may partly reflect differences in outcome definitions rather than fundamentally different biological patterns. Kikuchi et al used a stringent definition of CIA requiring two consecutive absolute neutrophil counts below 500/mm, ^{Reference Legge and Walters3} corresponding to the definition of true agranulocytosis. ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} Their analysis therefore specifically captured severe agranulocytosis rather than the broader spectrum of neutropenia examined by Zhou et al. ^{Reference Zhou, Luo, Siskind, Northwood, Tang and Lui1,Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} A clinically meaningful fall in neutrophil count may precede severe agranulocytosis, creating a temporal distinction between the first detectable haematological abnormality and the eventual fulfilment of a strict agranulocytosis definition. This distinction is important when comparing studies and when translating incidence data into monitoring policies. The Japanese study raises the possibility that early clozapine exposure may influence subsequent agranulocytosis rather than producing an immediate fall in neutrophil counts. Higher cumulative exposure during the first 30 days was associated with progressively greater CIA risk during the subsequent 180 days. Compared with the lowest exposure quartile, hazard ratios were 1.78, 2.01 and 3.07 for the second, third and fourth quartiles, respectively. ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} The median time to CIA was also shorter among patients with greater early cumulative exposure, decreasing from 97 days in the lowest quartile to 72 days in the highest. ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} These observations suggest a possible latency between early exposure intensity and clinically manifest agranulocytosis.

This finding is relevant to the interpretation of the Hong Kong study because it suggests that ‘when the risk factor occurs’ and ‘when the adverse event becomes clinically apparent’ may not be identical. Clozapine-induced inflammatory reactions such as fever and myocarditis often occur shortly after treatment initiation, whereas agranulocytosis generally develops later. ^{Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5–Reference Myles, Myles, Xia, Large, Kisely and Galletly7} Although the mechanisms underlying these adverse reactions remain incompletely understood, early exposure may represent a susceptibility-priming event rather than an immediate cause of neutrophil depletion. Accordingly, a monitoring policy based solely on the time of observed agranulocytosis may overlook clinically relevant biological processes initiated during the first weeks of treatment.

The issue of titration is particularly relevant in Japan. Clozapine remains substantially underused in Japan despite its established efficacy for treatment-resistant schizophrenia. ^{Reference Nagamine8} Recent Japanese work has argued that the conventional Japanese titration schedule may be unnecessarily rapid for some patients and that slower, individualised titration can reduce inflammatory adverse events while preserving clinical efficacy. ^{Reference Nagamine8} In a recent Japanese report, smaller dose increments and slower escalation were associated with substantially less clozapine-induced fever, supporting the concept that the initial treatment process itself may be a modifiable determinant of safety. ^{Reference Nagamine8} The findings of Kikuchi et al extend this concept by suggesting that early cumulative exposure may also be relevant to subsequent agranulocytosis.

Therefore, the implications of the Hong Kong study may extend beyond the question of whether monitoring should be reduced after a particular number of weeks or years. A more useful framework might integrate three dimensions: when haematological risk is greatest, which patients are particularly susceptible and which treatment-process factors are modifiable? Age and gender may contribute to risk stratification, as suggested by both Asian and international data-sets. ^{Reference Zhou, Luo, Siskind, Northwood, Tang and Lui1,Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5,Reference Rubio, Kane, Tanskanen, Tiihonen and Taipale6} Early cumulative dose and titration intensity should also be considered, although the observational nature of the Japanese study prevents causal conclusions. Other potential determinants, including concomitant medications, genetic susceptibility and pharmacokinetic characteristics, warrant further investigation. ^{Reference Legge and Walters3,Reference Kikuchi, Li, Komatsu, Yasui-Furukori, Inada and Tomita5} These observations should not be interpreted as an argument for simply abandoning long-term monitoring. Large registry studies have shown that the risk of agranulocytosis becomes very low after the first year but does not necessarily become zero. ^{Reference Rubio, Kane, Tanskanen, Tiihonen and Taipale6} Thus, the most appropriate future strategy may be neither indefinite intensive monitoring nor unrestricted relaxation, but risk-adapted surveillance that is particularly intensive during the early treatment period and progressively individualised thereafter.

The Hong Kong study therefore represents an important step towards rationalising clozapine monitoring in Asia. When considered together with the Japanese nationwide findings, it suggests that the optimal safety strategy should combine time-sensitive haematological surveillance with attention to early cumulative exposure and individualised titration. Such an approach could potentially preserve the principal safety benefit of blood monitoring while reducing unnecessary barriers to clozapine treatment. For East Asian clinical practice, the central question may therefore be shifting from ‘How long should every patient be monitored?’ to ‘How can monitoring intensity and treatment initiation be matched to the patient’s evolving risk?’